Abstract
Plasmid DNA (pDNA)-based gene therapy is a promising strategy for treating many chronic diseases and pathological states. Using pDNA has several advantages such as the sustained synthesis of proteins and peptides in their natives form, ease of the combined use of two or more bioactive factors, and cost-effectiveness. For effective pDNA delivery, cationic polymers are good candidates providing high pDNAstability and functionality.In this article, the development of polyplex nanomicelles composed of poly(ethyleneglycol) (PEG)-polycation block copolymers and pDNA as well as their future prospects is reviewed. The issues of safety and the transfection efficiency are highlighted for considerations of in vivo pDNA delivery.
Keywords: Gene therapy, Polyplexnanomicelle, Polycation, Biocompatibility, Toxicity, Non-viral gene delivery, Plasmid DNA, chronic diseases, pathological states, polymers
Current Gene Therapy
Title: Progress and Prospects of Polyplex Nanomicelles for Plasmid DNA Delivery
Volume: 11 Issue: 6
Author(s): Keiji Itaka and Kazunori Kataoka
Affiliation:
Keywords: Gene therapy, Polyplexnanomicelle, Polycation, Biocompatibility, Toxicity, Non-viral gene delivery, Plasmid DNA, chronic diseases, pathological states, polymers
Abstract: Plasmid DNA (pDNA)-based gene therapy is a promising strategy for treating many chronic diseases and pathological states. Using pDNA has several advantages such as the sustained synthesis of proteins and peptides in their natives form, ease of the combined use of two or more bioactive factors, and cost-effectiveness. For effective pDNA delivery, cationic polymers are good candidates providing high pDNAstability and functionality.In this article, the development of polyplex nanomicelles composed of poly(ethyleneglycol) (PEG)-polycation block copolymers and pDNA as well as their future prospects is reviewed. The issues of safety and the transfection efficiency are highlighted for considerations of in vivo pDNA delivery.
Export Options
About this article
Cite this article as:
Itaka Keiji and Kataoka Kazunori, Progress and Prospects of Polyplex Nanomicelles for Plasmid DNA Delivery, Current Gene Therapy 2011; 11 (6) . https://dx.doi.org/10.2174/156652311798192879
DOI https://dx.doi.org/10.2174/156652311798192879 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia
Current Drug Safety Hepatic Injury to the Newborn Liver Due to Drugs
Current Pharmaceutical Design Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Cardiovascular & Hematological Agents in Medicinal Chemistry Preeclampsia - Current Management and Future Approach
Current Pharmaceutical Biotechnology Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology COX-2 and the Kidneys
Current Pharmaceutical Design New Biotechnological Methods to Reduce Oxidative Stress in the Cardiovascular System: Focusing on the Bach1/Heme Oxygenase-1 Pathway
Current Pharmaceutical Biotechnology Preparation and Evaluation of Novel Expandable Drug Delivery System with Captopril
Current Drug Therapy Stability-indicating UPLC-PDA Method for Ambrisentan Tablets and Identification of a Main Degradation Product by UPLC-MS/MS
Current Pharmaceutical Analysis Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation
Protein & Peptide Letters The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Current Medicinal Chemistry Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Comparison of Clinical Features at the Onset of Takayasu’s Arteritis According to Age and Sex
Current Vascular Pharmacology Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers
Current Pharmaceutical Design Blood-brain Barrier Disruption May Contribute to White Matter Lesions in the Setting of Internal Jugular Venous Stenosis
Current Neurovascular Research Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued)